Therapy response – splenic disease responded to treatment & stays in remission

Baseline PET – splenomegaly
Stage 1S

Surveillance PET (6 weeks post-treatment)

Surveillance PET (1 year post-treatment)

http://humanhealth.iaea.org
Restaging PET during treatment - Progressive metabolic response to treatment

Baseline PET – Stage 4E

Mid-cycle PET
Partial metabolic response

Post-treatment PET
Complete metabolic response
Surveillance PET scan for stage 3 follicular NHL – early recurrence detected on PET (no CT done) → stem cell transplant

Surveillance PET (9 months post-treatment) Negative PET

Surveillance PET (1 year post-treatment) Recurrent disease

3 months post-stem cell transplant Negative PET

http://humanhealth.iaea.org
Surveillance PET
- Continued metabolic response to initial treatment

Baseline Stage 4E

Post-treatment (6 weeks)

Post-treatment (6 months)

Post-treatment (1 year)
Therapy response in Hodgkin’s lymphoma – complete metabolic response within a residual mediastinal mass on CT
Teaching points

• FDG PET is the method of choice for the assessment of response to therapy in Hodgkin’s and non-Hodgkin’s lymphomas as it is superior to the CT based criteria.

• FDG PET can characterise residual masses.

• The absence or persistence of FDG uptake during chemotherapy can provide prognostic information.

• FDG PET identification of non-responders can result in a change of management.